Genetic testing for paediatric neurological disorders

Borry, 2007 1995, ASHG/ACMG report. Points to consider: ethical, legal and psychosocial implications of genetic testing in children and adolescents, Am J Hum Genet, 57, 1233 McNally, 2004, Research and development of genetic tests, 51 Harper, 2004, Genetics and society, 369 Sequeiros Harper, 2004, Glossary, 381 Wang, 2007, Consensus statement for standard of care in spinal muscular atrophy, J Child Neurol, 22, 1027, 10.1177/0883073807305788 Prior, 2005, Experience and strategy for the molecular testing of Duchenne muscular dystrophy, J Mol Diagn, 7, 317, 10.1016/S1525-1578(10)60560-0 Winship, 2008, Lessons from the skin—cutaneous features of familial cancer, Lancet Oncol, 9, 462, 10.1016/S1470-2045(08)70126-8 Viskochil, 2005, Neurofibromatosis type 1, 369 Novak, 2007, The phakomatoses: dermatologic clues to neurologic anomalies, Semin Pediatr Neurol, 14, 140, 10.1016/j.spen.2007.07.007 Tassin, 2000, Levodopa-responsive dystonia. GTP cyclohydrolase I or parkin mutations?, Brain, 123, 1112, 10.1093/brain/123.6.1112 Leutenegger, 2006, Juvenile-onset Parkinsonism as a result of the first mutation in the adenosine triphosphate orientation domain of PINK1, Arch Neurol, 63, 1257, 10.1001/archneur.63.9.1257 Beck, 2007, New therapeutic options for lysosomal storage disorders: enzyme replacement, small molecules and gene therapy, Hum Genet, 121, 1, 10.1007/s00439-006-0280-4 Kalviainen, 2008, Clinical picture of EPM1-Unverricht-Lundborg disease, Epilepsia, 49, 549, 10.1111/j.1528-1167.2008.01546.x Eldridge, 1983, ‘Baltic’ myoclonus epilepsy: hereditary disorder of childhood made worse by phenytoin, Lancet, 2, 838, 10.1016/S0140-6736(83)90749-3 van Ommen, 2008, The therapeutic potential of antisense-mediated exon skipping, Curr Opin Mol Ther, 10, 140 Valente, 2008, Genotypes and phenotypes of Joubert syndrome and related disorders, Eur J Med Genet, 51, 1, 10.1016/j.ejmg.2007.11.003 Castori, 2005, NPHP1 gene deletion is a rare cause of Joubert syndrome related disorders, J Med Genet, 42, e9, 10.1136/jmg.2004.027375 Depienne, 2007, Hereditary spastic paraplegias: an update, Curr Opin Neurol, 20, 674, 10.1097/WCO.0b013e3282f190ba Borry Borry, 2007, Carrier testing in minors: conflicting views, Nat Rev Genet, 8, 828, 10.1038/nrg2222 Cruz, 2007, Molecular analysis of the Von Hippel-Lindau (VHL) gene in a family with non-syndromic pheochromocytoma: the importance of genetic testing, Arq Bras Endocrinol Metabol, 51, 1463, 10.1590/S0004-27302007000900008 2003, American Society of Clinical Oncology policy statement update: genetic testing for cancer susceptibility, J Clin Oncol, 21, 2397, 10.1200/JCO.2003.03.189 Waisbren, 2008, expanded newborn screening: information and resources for the family physician, Am Fam Physician, 77, 987 Rantanen, 2008, What is ideal genetic counselling? A survey of current international guidelines, Eur J Hum Genet, 16, 445, 10.1038/sj.ejhg.5201983 2007, Principles and best practices for quality assurance of molecular genetic testing, 11 Wisniewski Dallapiccola, 2006, Genetic testing in Italy, year 2004, Eur J Hum Genet, 14, 911, 10.1038/sj.ejhg.5201653 Prior, 2007, Spinal muscular atrophy diagnostics, J Child Neurol, 22, 952, 10.1177/0883073807305668 Campuzano, 1996, Friedreich's ataxia: autosomal recessive disease caused by an intronic GAA triplet repeat expansion, Science, 271, 1423, 10.1126/science.271.5254.1423 Durr, 1996, Clinical and genetic abnormalities in patients with Friedreich's ataxia, N Engl J Med, 335, 1169, 10.1056/NEJM199610173351601 Ala, 2007, Wilson's disease, Lancet, 369, 397, 10.1016/S0140-6736(07)60196-2 Gojova, 2008, Genotyping microarray as a novel approach for the detection of ATP7B gene mutations in patients with Wilson disease, Clin Genet, 73, 441, 10.1111/j.1399-0004.2008.00989.x Mavrou, 2008, The ATM gene and ataxia telangiectasia, Anticancer Res, 28, 401 Francke, 2006, Mechanisms of disease: neurogenetics of MeCP2 deficiency, Nat Clin Pract Neurol, 2, 212, 10.1038/ncpneuro0148 Nave, 2007, Mechanisms of disease: inherited demyelinating neuropathies—from basic to clinical research, Nat Clin Pract Neurol, 3, 453, 10.1038/ncpneuro0583 Williams, 2006, Diagnosis of the neuronal ceroid lipofuscinoses: an update, Biochim Biophys Acta, 1762, 865, 10.1016/j.bbadis.2006.07.001 Horsthemke, 2008, Mechanisms of imprinting of the Prader-Willi/Angelman region, Am J Med Genet A, 146A, 2041, 10.1002/ajmg.a.32364 Ayme, 2000, Bridging the gap between molecular genetics and metabolic medicine: access to genetic information, Eur J Pediatr, 159, S183, 10.1007/PL00014399 Uhlmann, 2008, Key internet genetic resources for the clinician, JAMA, 299, 1356, 10.1001/jama.299.11.1356 2003, Medicare, Medicaid, and CLIA programs; laboratory requirements relating to quality systems and certain personnel qualifications. Final rule, Fed Regist, 68, 3639 Stultiens, 2007, Minors and informed consent: a comparative approach, Eur J Health Law, 14, 21, 10.1163/092902707X182788 Rantanen, 2008, Regulations and practices of genetic counselling in 38 European countries: the perspective of national representatives, Eur J Hum Genet, 16, 1208, 10.1038/ejhg.2008.93 Isken, 2007, Quality control of eukaryotic mRNA: safeguarding cells from abnormal mRNA function, Genes Dev, 21, 1833, 10.1101/gad.1566807 Van Der Knaap, 2006, Vanishing white matter disease, Lancet Neurol, 5, 413, 10.1016/S1474-4422(06)70440-9 Li, 2004, Mutations linked to leukoencephalopathy with vanishing white matter impair the function of the eukaryotic initiation factor 2B complex in diverse ways, Mol Cell Biol, 24, 3295, 10.1128/MCB.24.8.3295-3306.2004 Moser, 2007, X-linked adrenoleukodystrophy, Nat Clin Pract Neurol, 3, 140, 10.1038/ncpneuro0421 Opal, 2002, Intrafamilial phenotypic variability of the DYT1 dystonia: from asymptomatic TOR1A gene carrier status to dystonic storm, Mov Disord, 17, 339, 10.1002/mds.10096 Edwards, 2003, Unusual phenotypes in DYT1 dystonia: a report of five cases and a review of the literature, Mov Disord, 18, 706, 10.1002/mds.10411 Gambarin, 2006, Atypical phenotypes and clinical variability in a large Italian family with DYT1-primary torsion dystonia, Mov Disord, 21, 1782, 10.1002/mds.21056 Kostic, 2006, Intrafamilial phenotypic and genetic heterogeneity of dystonia, J Neurol Sci, 250, 92, 10.1016/j.jns.2006.07.010 Risch, 2007, Intragenic CIS and TRANS modification of genetic susceptibility in DYT1 torsion dystonia, Am J Hum Genet, 80, 1188, 10.1086/518427 Jozwiak, 2008, Possible mechanisms of disease development in tuberous sclerosis, Lancet Oncol, 9, 73, 10.1016/S1470-2045(07)70411-4 Grabowski, 2003, The epsilon-sarcoglycan gene (SGCE), mutated in myoclonus-dystonia syndrome, is maternally imprinted, Eur J Hum Genet, 11, 138, 10.1038/sj.ejhg.5200938 Muller, 2002, Evidence that paternal expression of the epsilon-sarcoglycan gene accounts for reduced penetrance in myoclonus-dystonia, Am J Hum Genet, 71, 1303, 10.1086/344531 Gatchel, 2005, Diseases of unstable repeat expansion: mechanisms and common principles, Nat Rev Genet, 6, 743, 10.1038/nrg1691 Korneluk, 1997, Anticipating anticipation, Nat Genet, 15, 119, 10.1038/ng0297-119 Ribai, 2007, Psychiatric and cognitive difficulties as indicators of juvenile huntington disease onset in 29 patients, Arch Neurol, 64, 813, 10.1001/archneur.64.6.813 Redman, 1993, Relationship between parental trinucleotide GCT repeat length and severity of myotonic dystrophy in offspring, JAMA, 269, 1960, 10.1001/jama.1993.03500150072029 Ohya, 1997, Detection of the CTG repeat expansion in congenital myotonic dystrophy, Jpn J Hum Genet, 42, 169, 10.1007/BF02766919 Caskey, 1992, Triplet repeat mutations in human disease, Science, 256, 784, 10.1126/science.1589758 Van Esch, 2006, The Fragile X premutation: new insights and clinical consequences, Eur J Med Genet, 49, 1, 10.1016/j.ejmg.2005.11.001 Hagerman, 2004, The fragile-X premutation: a maturing perspective, Am J Hum Genet, 74, 805, 10.1086/386296 Fackenthal, 2005, Denaturing high-performance liquid chromatography for mutation detection and genotyping, Methods Mol Biol, 311, 73 Hedrich, 2004, Distribution, type, and origin of Parkin mutations: review and case studies, Mov Disord, 19, 1146, 10.1002/mds.20234 Badano, 2002, Beyond Mendel: an evolving view of human genetic disease transmission, Nat Rev Genet, 3, 779, 10.1038/nrg910 Katsanis, 2003, Triallelic inheritance in Bardet-Biedl syndrome, a mendelian recessive disorder, Science, 293, 2256, 10.1126/science.1063525 Badano, 2006, Dissection of epistasis in oligogenic Bardet-Biedl syndrome, Nature, 439, 326, 10.1038/nature04370 Depienne, 2007, Exon deletions of SPG4 are a frequent cause of hereditary spastic paraplegia, J Med Genet, 44, 281, 10.1136/jmg.2006.046425 Grunewald, 2008, Myoclonus-dystonia: significance of large SGCE deletions, Hum Mutat, 29, 331, 10.1002/humu.9521 Harper, 2004, Genetic counselling in mendelian disorders, 21 Morava, 2006, Mitochondrial disease criteria: diagnostic applications in children, Neurology, 67, 1823, 10.1212/01.wnl.0000244435.27645.54 Zeviani, 2007, Mitochondrial disorders, Curr Opin Neurol, 20, 564, 10.1097/WCO.0b013e3282ef58cd Moslemi, 2007, Molecular genetic and clinical aspects of mitochondrial disorders in childhood, Mitochondrion, 7, 241, 10.1016/j.mito.2007.02.002 Thorburn, 2001, Mitochondrial disorders: genetics, counseling, prenatal diagnosis and reproductive options, Am J Med Genet, 106, 102, 10.1002/ajmg.1380 South, 2008, Genomic medicine in prenatal diagnosis, Clin Obstet Gynecol, 51, 62, 10.1097/GRF.0b013e3181616509 Bredenoord, 2008, Dealing with uncertainties: ethics of prenatal diagnosis and preimplantation genetic diagnosis to prevent mitochondrial disorders, Hum Reprod Update, 14, 83, 10.1093/humupd/dmm037 2007, Preimplantation genetic testing: a Practice Committee opinion, Fertil Steril, 88, 1497, 10.1016/j.fertnstert.2007.10.010 Renwick, 2007, Preimplantation genetic diagnosis for monogenic diseases: overview and emerging issues, Expert Rev Mol Diagn, 7, 33, 10.1586/14737159.7.1.33 McNally, 2004, Genetic testing: state of the art, 15 Sellner, 2004, MLPA and MAPH: new techniques for detection of gene deletions, Hum Mutat, 23, 413, 10.1002/humu.20035 Slater, 2004, Improved testing for CMT1A and HNPP using multiplex ligation-dependent probe amplification (MLPA) with rapid DNA preparations: comparison with the interphase FISH method, Hum Mutat, 24, 164, 10.1002/humu.20072 Bunyan, 2007, Simultaneous MLPA-based multiplex point mutation and deletion analysis of the dystrophin gene, Mol Biotechnol, 35, 135, 10.1007/BF02686108 Kozlowski, 2007, Identification of 54 large deletions/duplications in TSC1 and TSC2 using MLPA, and genotype-phenotype correlations, Hum Genet, 121, 389, 10.1007/s00439-006-0308-9 Zeng, 2008, Array-MLPA: comprehensive detection of deletions and duplications and its application to DMD patients, Hum Mutat, 29, 190, 10.1002/humu.20613 Das, 2008, Molecular genetic testing for ultra rare diseases: models for translation from the research laboratory to the CLIA-certified diagnostic laboratory, Genet Med, 10, 332, 10.1097/GIM.0b013e318172838d 2007, ASHG statement on direct-to-consumer genetic testing in the United States, Am J Hum Genet, 81, 635, 10.1086/521634